The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a unique opportunity to learn about many new developments in multiple sclerosis (MS). Areas covered include epidemiology, genetics, pathology, biomarkers, imaging, immunology and treatment.
This year ECTRIMS gives special attention to efficient treatment for progressive MS. The focus will be on the better understanding of risk factors and mechanisms MS, as well as biomarkers, study design and novel treatment approaches.
The program offers scientific and educational sessions and plenary lectures, as well as “Hot Topic”, “Young Investigator” and poster sessions. “Hot Topics” this year range from diagnosis and treatment to disease mechanisms, with some captivating issues being covered, including whether or not MS is becoming a milder disease, and when to stop or resume treatment during pregnancy. There will also be some insights into stem cell treatment, and epigenetics in MS pathogenesis and disease management.
ECTRIMS 2019 will also feature an interactive debate on prescribing 1st generation injectables to newly diagnosed patients with active relapsing MS. If you are in the audience, you can tweet your comments and questions during the presentations, and vote for the winner at the end.
The scientific sessions will cover a wide range of topics including “Socioeconomic outcomes in MS”, “Immunopathogenesis and antigen-specific therapies” and “Quantitative imaging biomarkers” amongst others.
Click here to learn more about the full program of this year’s ECTRIMS Congress.